ARTICLE | Clinical News
Ascenta preclinical data
May 11, 2009 7:00 AM UTC
AT-406 was active as a single agent in several mouse models of cancer, as well as in breast, lung, pancreatic, prostate and bladder cancer cell lines in vitro. Additionally, AT-406 plus combination ty...